PAI-1 Level Differences in Malignant Plural Effusion, Parapneumonic Pleuritis, and Cardiac Hydrothorax.
malignant pleural effusion
plasminogen activator inhibitor-1
pleural effusion
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
04 Sep 2019
04 Sep 2019
Historique:
received:
27
06
2019
revised:
08
08
2019
accepted:
30
08
2019
entrez:
7
9
2019
pubmed:
7
9
2019
medline:
24
3
2020
Statut:
epublish
Résumé
Plasminogen activator inhibitor-1 (PAI-1) is a fibrinolytic system enzyme whose role in various fibrinolytic processes is currently unknown. In clinical manifestations of pleural liquids of diverse etiology, various levels of fibrinolytic activity can be observed-parapneumonic processes tend to loculate in fibrin septa, while malignant pleural effusion (MPE) does not. The purpose of this study was to determine possible differences in PAI-1 levels in pleural effusions of varied etiology. PAI-1 level in pleural effusion and serum was determined in 144 patients with pleural effusions of various etiology (cardiac hydrothorax-42 patients (29.2%), MPE-67 patients (46.5%), parapneumonic pleuritis-27 (18.8%), tuberculous pleuritis-6 patients (4.1%), pancreatogenic pleuritis-1 patient (0.7%) and pulmonary artery thromboembolism with pleuritis-1 patient (0.7%)). The median PAI-1 level (ng/mL) was the highest in the parapneumonic pleuritis group both in the effusion and the serum, with values of 291 (213-499) ng/mL and 204 (151-412) ng/mL, respectively, resulting in a statistically significant difference (p < 0.001) from the cardiac hydrothorax and MPE groups. However, there was no statistically significant difference between PAI-1 levels in the pleural effusion and serum in the cardiac hydrothorax and MPE groups. The PAI-1 level in MPE and cardiac hydrothorax was statistically significantly lower than in parapneumonic pleuritis.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Plasminogen activator inhibitor-1 (PAI-1) is a fibrinolytic system enzyme whose role in various fibrinolytic processes is currently unknown. In clinical manifestations of pleural liquids of diverse etiology, various levels of fibrinolytic activity can be observed-parapneumonic processes tend to loculate in fibrin septa, while malignant pleural effusion (MPE) does not. The purpose of this study was to determine possible differences in PAI-1 levels in pleural effusions of varied etiology.
MATERIAL AND METHODS
METHODS
PAI-1 level in pleural effusion and serum was determined in 144 patients with pleural effusions of various etiology (cardiac hydrothorax-42 patients (29.2%), MPE-67 patients (46.5%), parapneumonic pleuritis-27 (18.8%), tuberculous pleuritis-6 patients (4.1%), pancreatogenic pleuritis-1 patient (0.7%) and pulmonary artery thromboembolism with pleuritis-1 patient (0.7%)).
RESULTS
RESULTS
The median PAI-1 level (ng/mL) was the highest in the parapneumonic pleuritis group both in the effusion and the serum, with values of 291 (213-499) ng/mL and 204 (151-412) ng/mL, respectively, resulting in a statistically significant difference (p < 0.001) from the cardiac hydrothorax and MPE groups. However, there was no statistically significant difference between PAI-1 levels in the pleural effusion and serum in the cardiac hydrothorax and MPE groups.
CONCLUSION
CONCLUSIONS
The PAI-1 level in MPE and cardiac hydrothorax was statistically significantly lower than in parapneumonic pleuritis.
Identifiants
pubmed: 31487930
pii: medicina55090567
doi: 10.3390/medicina55090567
pmc: PMC6780168
pii:
doi:
Substances chimiques
Plasminogen Activator Inhibitor 1
0
SERPINE1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Chest. 2005 Aug;128(2):690-7
pubmed: 16100155
Eur Respir J. 1997 Aug;10(8):1907-13
pubmed: 9272937
Am Rev Respir Dis. 1991 Jul;144(1):187-94
pubmed: 2064128
Int J Lab Hematol. 2007 Apr;29(2):132-8
pubmed: 17474886
Curr Drug Targets. 2007 Sep;8(9):1030-41
pubmed: 17896954
Eur Respir J. 1995 Aug;8(8):1352-6
pubmed: 7489803
Thromb Haemost. 2008 Dec;100(6):1029-36
pubmed: 19132226
Clin Immunol. 2005 Aug;116(2):166-73
pubmed: 15897010
Respirology. 2018 Jan;23(1):89-95
pubmed: 28836366
Physiol Rev. 1993 Jan;73(1):161-95
pubmed: 8419965
J Natl Cancer Inst. 2001 Jun 20;93(12):913-20
pubmed: 11416112
Biomed Pharmacother. 2018 Sep;105:83-94
pubmed: 29852393
PLoS One. 2013;8(1):e53169
pubmed: 23308155